Generating pre-clinical human data for therapeutic candidates with in-vitro liver and metabolic disease models.
pixlbio (formerly DefiniGEN) has raised $136K in total funding. The most recent round was Undisclosed. The last funding was announced in November 2024.
pixlbio (formerly DefiniGEN)'s investors include Business Growth Fund, 24 Haymarket, Parkwalk Advisors, University of Cambridge Enterprise, Jonathan Milner.
pixlbio (formerly DefiniGEN) is headquartered in Cambridge, United Kingdom.
Generating pre-clinical human data for therapeutic candidates with in-vitro liver and metabolic disease models.
pixlbio (formerly DefiniGEN) is at the Undisclosed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"pixlbio (formerly DefiniGEN) — Funding & Investors." VCBacked, November 28, 2024, https://www.vcbacked.co/company/pixlbio-formerly-definigen. Accessed October 2, 2026.
VCBacked. (2024). pixlbio (formerly DefiniGEN) — Funding & Investors. Retrieved October 2, 2026, from https://www.vcbacked.co/company/pixlbio-formerly-definigen
{{cite web |title=pixlbio (formerly DefiniGEN) — Funding & Investors |url=https://www.vcbacked.co/company/pixlbio-formerly-definigen |website=VCBacked |access-date=October 2, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated